Evidence map›Paper›PMID 35707405›Full record

ArticleRespiratory medicine case reports2022

A case of autoimmune pulmonary alveolar proteinosis with severe respiratory failure treated with segmental lung lavage and oral statin therapy.

Tomotsugu Takano, Keisuke Takeda, Satoshi Nakamura, Genta Akiyama, Nobuhisa Ando, Masashi Komori

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tomotsugu TakanoDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Fukuoka, Japan.
Keisuke TakedaDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Fukuoka, Japan.
Satoshi NakamuraDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Fukuoka, Japan.
Genta AkiyamaDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Fukuoka, Japan.
Nobuhisa AndoDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Fukuoka, Japan.
Masashi KomoriDepartment of Respiratory Medicine, Steel Memorial Yawata Hospital, Fukuoka, Japan.
Nippon Steel Yawata Memorial Hospital · JPKyushu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary alveolar proteinosis (PAP) is a diffuse lung disease characterized by the accumulation of alveolar surfactants due to dysfunction of granulocyte-macrophage colony-stimulating factor-dependent cholesterol clearance. Whole-lung lavage is the current standard of care for PAP, but it can lead to the exacerbation of hypoxia. A medication targeting cholesterol homeostasis is a promising therapy for refractory PAP. We present a case of autoimmune PAP with severe hypoxia that was successfully treated with segmental lung lavage (SLL). Following SLL for disease relapse, statin treatment for dyslipidemia was started. After initiating statin treatment, the patient did not require bronchoalveolar lavage for 10 months.

Indexed as

BAL, bronchoalveolar lavageCT, computed tomographyDyslipidemiaECMO, extracorporeal membrane oxygenationGM-CSF, granulocyte-macrophage colony-stimulating factorGranulocyte-macrophage colony-stimulating factorHOT, home oxygen therapyNon-invasive cholesterol treatmentPAP, pulmonary alveolar proteinosisPulmonary alveolar proteinosisSegmental lung lavageSLL, segmental lung lavageWhole lung lavageWLL, whole-lung lavage

Identifiers

PMID35707405
PMCPMC9190053
OpenAlexW4281855612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.